Publications by authors named "F Scheiflinger"

Claim this Profile
P
Preclinical development of TAK-754, a high-performance AAV8-based vector expressing coagulation factor VIII.
Johannes Lengler, Markus Weiller, Franziska Horling, Josef Mayrhofer, Maria Schuster, Friedrich Scheiflinger

Mol Ther Methods Clin Dev· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell disease.
Paolo Rossato, Helmut Glantschnig, Fabio Canneva, Maria Schuster, Sogue Coulibaly, Friedrich Scheiflinger

J Thromb Haemost· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease.
Paolo Rossato, Enrica Federti, Alessandro Matte, Helmut Glantschnig, Fabio Canneva, Friedrich Scheiflinger

Haematologica· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of exaggerated pharmacology by recombinant ADAMTS13 in the rat and monkey.
Paolo Rossato, Helmut Glantschnig, Peter Leidenmühler, Alexandra Kopic, Tanja Ruthsatz, Friedrich Scheiflinger

Blood Coagul Fibrinolysis· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency.
Wenjing Cao, Biao Dong, Franziska Horling, Jenni A Firrman, Johannes Lengler, Friedrich Scheiflinger

Mol Ther Methods Clin Dev· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis